Femasys INC Form 4 insider transactions

Kenneth D. Eichenbaum, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Edward R Uzialko, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Alistair Milnes, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Charles Larsen, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs of Femasys Inc, purchased 3,125 shares of common stock on August 7, 2026 for $3.20 per share.

Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs of Femasys Inc, received 6,250 shares of common stock on July 6, 2026.

Jeremy Alexander Sipos, Chief Technology Officer of Femasys Inc, purchased 3,125 shares of common stock on August 7, 2026 for $3.20 per share.

John Charles Canning, Chief Operating Officer of Femasys Inc, purchased 4,375 shares of common stock on August 7, 2026 for $3.20 per share.

Dov Elefant, Chief Financial Officer of Femasys Inc, purchased 15,625 shares of common stock on August 7, 2026 for $3.20 per share.

Kathy Lee-Sepsick, Chief Executive Officer and a Director of Femasys Inc, purchased 15,625 shares of common stock on August 7, 2026 for $3.20 per share.

Femasys Inc.'s Chief Operating Officer, John Charles Canning, was granted 150,000 stock options with an exercise price of $0.38, vesting over four years.

Femasys Inc. CEO Kathy Lee-Sepsick acquired 68,244 Series D-1 Warrants with an exercise price of $0.58 per share in a private placement.

Femasys Inc.'s Chief Financial Officer, Dov Elefant, acquired 34,122 Series D-1 Warrants with an exercise price of $0.58 per share as part of an Omnibus Amendment and Consent Agreement.

Femasys Inc. Director Charles Larsen acquired 34,122 Series D-1 Warrants with an exercise price of $0.58 per share.

Femasys Director Kenneth D. Eichenbaum acquired 102,366 Series D-1 Warrants at an exercise price of $0.58 per share through a private placement.

Femasys Inc. Director Kenneth D. Eichenbaum was granted 35,200 stock options with an exercise price of $0.60, vesting over three years.

Femasys CEO Kathy Lee-Sepsick acquired $50,000 worth of convertible notes and warrants, signaling a long-term investment in the company.

Femasys Inc. Director Charles Larsen has acquired $25,000 worth of senior secured convertible notes and various series of warrants, signaling insider confidence.

Femasys CFO Dov Elefant has acquired senior secured convertible notes and three series of warrants, representing a direct investment in the company.

Femasys CFO Dov Elefant purchased 38,828 units, each comprising one common stock share and one warrant, in a public offering.

Femasys CEO Kathy Lee-Sepsick acquired 48,535 units, each comprising one common stock share and one warrant, in an underwritten public offering.

Femasys Inc. has granted 100,000 stock options to its Chief Commercial Officer, Nicholas Kelley Stinson, with an exercise price of $0.90 per share.

Femasys Inc. Director Edward R. Uzialko was granted 17,600 stock options with an exercise price of $0.98 per share, vesting one year from the grant date.

Femasys Inc. Director Alistair Milnes was granted 17,600 stock options with an exercise price of $0.98, vesting one year from the grant date.

Femasys Inc. Director Charles Larsen has been granted stock options to acquire 17,600 shares of common stock at an exercise price of $0.98 per share, vesting one year from the grant date.

Femasys Inc. Director and 10% Owner Joshua Silverman was granted 17,600 stock options with an exercise price of $0.98, vesting one year from the grant date.

Femasys Inc. Director and 10% Owner Charles Larsen acquired 24,510 shares of common stock at $1.02 per share on June 2, 2025, through an indirect ownership, pursuant to a Rule 10b5-1 trading plan.

Daniel Scott Currie, Chief Operating Officer of Femasys Inc. (FEMY), has acquired 19,608 shares of common stock indirectly through a family trust, signaling strong insider confidence in the company.

Femasys Inc.'s Chief Financial Officer, Dov Elefant, reported the indirect acquisition of 19,608 shares of common stock at $1.02 per share, effective June 2, 2025.

Femasys Inc. CEO and Director Kathy Lee-Sepsick has increased her beneficial ownership in the company through an indirect acquisition of common stock.